Key facts
- This page summarizes Adams Catherine Owen's Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 15 Jun 2023, 16:32.
Adams Catherine Owen - 13 Jun 2023 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)
- Reporting relationship
- Director
- Issuer ticker
- AGIO
- Reported as of
- 13 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Jun 2023, 16:32:15 UTC
- Prior SEC filing
- 09 Jun 2023
- Next SEC filing
- 07 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ William Cook, as attorney-in-fact for Catherine Owen
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adams Catherine Owen filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 15 Jun 2023.
Change
- Previous filing in this sequence was filed on 09 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGIO
transaction
Derivative
Restricted stock units
Award
- Transaction value
- $0
- Shares
- +5,929
- Change %
- Price
- $0.000000
- Shares after
- 5,929
- Date
- 13 Jun 2023
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 5,929
- Exercise price
- Footnotes
- F1, F2
AGIO
transaction
Derivative
Stock options (right to buy)
Award
- Transaction value
- $0
- Shares
- +33,177
- Change %
- Price
- $0.000000
- Shares after
- 33,177
- Date
- 13 Jun 2023
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 33,177
- Exercise price
- $26.56
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
Footnote F2
The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
Footnote F3
This option was granted on June 13, 2023. The shares underlying this option vest as to 25% of the underlying shares on June 13, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.